Beam Therapeutics Inc. (BEAM)
BEAM Stock Price Chart
Explore Beam Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze BEAM price movements and trends.
BEAM Company Profile
Discover essential business fundamentals and corporate details for Beam Therapeutics Inc. (BEAM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Feb 2020
Employees
393.00
Website
https://www.beamtx.comCEO
John Evans
Description
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Financial Timeline
Browse a chronological timeline of Beam Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$1.11, while revenue estimate is $16.37m.
Earnings released on 7 May 2026
EPS came in at -$0.91 falling short of the estimated -$0.87 by -4.60%, while revenue for the quarter reached $31.74m , beating expectations by +189.13%.
Earnings released on 24 Feb 2026
EPS came in at -$0.10 surpassing the estimated -$1.13 by +91.15%, while revenue for the quarter reached $114.11m , beating expectations by +877.88%.
Earnings released on 4 Nov 2025
EPS came in at -$1.10 falling short of the estimated -$0.98 by -12.24%, while revenue for the quarter reached $9.70m , missing expectations by -26.61%.
Earnings released on 5 Aug 2025
EPS came in at -$1.00 surpassing the estimated -$1.04 by +3.85%, while revenue for the quarter reached $8.47m , missing expectations by -26.62%.
Earnings released on 6 May 2025
EPS came in at -$1.24 falling short of the estimated -$1.11 by -11.71%, while revenue for the quarter reached $7.47m , missing expectations by -51.86%.
Earnings released on 25 Feb 2025
EPS came in at -$1.09 surpassing the estimated -$1.25 by +12.80%, while revenue for the quarter reached $30.07m , beating expectations by +82.51%.
Earnings released on 5 Nov 2024
EPS came in at -$1.17 falling short of the estimated -$1.13 by -3.54%, while revenue for the quarter reached $14.27m , missing expectations by -5.64%.
Earnings released on 6 Aug 2024
EPS came in at -$1.11 surpassing the estimated -$1.13 by +1.77%, while revenue for the quarter reached $11.77m , missing expectations by -14.26%.
Earnings released on 7 May 2024
EPS came in at -$1.21 surpassing the estimated -$1.45 by +16.55%, while revenue for the quarter reached $7.41m , missing expectations by -56.33%.
Earnings released on 27 Feb 2024
EPS came in at $1.73 surpassing the estimated -$1.01 by +271.29%, while revenue for the quarter reached $316.19m , beating expectations by +1.59k%.
Earnings released on 8 Nov 2023
EPS came in at -$1.22 surpassing the estimated -$1.37 by +10.95%, while revenue for the quarter reached $17.19m , missing expectations by -13.65%.
Earnings released on 8 Aug 2023
EPS came in at -$1.08 surpassing the estimated -$1.38 by +21.74%, while revenue for the quarter reached $20.12m , beating expectations by +11.45%.
Earnings released on 10 May 2023
EPS came in at -$1.33 surpassing the estimated -$1.36 by +2.21%, while revenue for the quarter reached $24.21m , beating expectations by +71.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.54 surpassing the estimated -$1.32 by +59.09%, while revenue for the quarter reached $20.04m , beating expectations by +57.61%.
Earnings released on 7 Nov 2022
EPS came in at -$1.56 falling short of the estimated -$1.30 by -20.00%, while revenue for the quarter reached $15.80m , beating expectations by +120.95%.
Earnings released on 9 Aug 2022
EPS came in at -$1.02 surpassing the estimated -$1.08 by +5.56%, while revenue for the quarter reached $16.65m , beating expectations by +98.48%.
Earnings released on 9 May 2022
EPS came in at -$1.01 surpassing the estimated -$1.10 by +8.18%, while revenue for the quarter reached $8.43m , missing expectations by -80.90%.
Earnings released on 28 Feb 2022
EPS came in at -$0.85 surpassing the estimated -$1.02 by +16.67%, while revenue for the quarter reached $51.07m , beating expectations by +496.37%.
Earnings released on 8 Nov 2021
EPS came in at -$0.42 surpassing the estimated -$0.78 by +46.15%, while revenue for the quarter reached $763.00k , missing expectations by -32.48%.
Earnings released on 10 Aug 2021
EPS came in at -$0.95 falling short of the estimated -$0.58 by -63.79%, while revenue for the quarter reached $6.00k , beating expectations by +11.62%.
BEAM Stock Performance
Access detailed BEAM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
